BHCM
CORT icon

Boulder Hill Capital Management’s Corcept Therapeutics CORT Stock Holding History

Boulder Hill Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,600
Closed -$400K – 150
2022
Q3 		$400K Buy
+15,600
New +$417K 0.3% 80

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Boulder Hill Capital Management's CORT Position: Q4 2022 in Review

Boulder Hill Capital Management sold out of Corcept Therapeutics (CORT) in Q4 2022, closing a stake of 15,600 shares — an estimated $400K sold.

Boulder Hill Capital Management first reported a position in CORT in Q3 2022 and held it in 1 quarter. The position peaked at $400K in Q3 2022. 241 funds tracked by Wall St. Rank hold CORT as of Q4 2022.

  • Boulder Hill Capital Management reported no remaining Corcept Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Boulder Hill Capital Management sold 15,600 Corcept Therapeutics shares in Q4 2022, an estimated $400K.
  • Boulder Hill Capital Management first reported a position in Corcept Therapeutics in Q3 2022 and held it in 1 quarter.
  • Boulder Hill Capital Management's Corcept Therapeutics position peaked at $400K in Q3 2022.
  • 241 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2022.

Based on Boulder Hill Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.